International Medical Case Reports Journal, 2021 João Heitor Marques,1 Ana Carolina Abreu,1 Nisa Silva,1 Angelina Meireles,1,2 Bernardete Pessoa,1,2 João Melo Beirão1,2 1Serviço de Oftalmologia, Centro Hospitalar e Universitário do Porto, Porto, Portugal; 2Instituto ...
Marques JH +5 more
doaj
Treatment Strategies for Refractory Diabetic Macular Edema: Switching Anti-VEGF Treatments, adopting corticosteroid-based treatments, and combination therapy [PDF]
, 2016 Introduction: The pathophysiology of diabetic macular edema (DME) is complex, involving vascular endothelial growth factor (VEGF) and other inflammatory mediators.
Ciulla, Thomas A., Hussain, Rehan M.
core +1 more source
Therapeutic Advances in Ophthalmology, 2019 Introduction: Macular edema after central retinal vein occlusion is a common cause of vision loss. Upregulation of vascular endothelial growth factor and higher levels of inflammatory mediators have been involved in the pathogeny of the macular edema in ...
João Coelho +2 more
doaj +1 more source
Sustained-release steroids for the treatment of diabetic macular edema. [PDF]
, 2015 Glucocorticoids have been used for decades in the treatment of ocular disorders via topical, periocular, and more recently intravitreal routes. However, their exact mechanisms of action on ocular tissues remain imperfectly understood.
Behar-Cohen, F., Daruich, A., Matet, A.
core +1 more source
An eighteen-month follow-up study on the effects of intravitreal dexamethasone implant in diabetic macular edema refractory to anti-VEGF therapy [PDF]
, 2016 AIM: To evaluate the long-term efficacy and safety of dexamethasone implants in subjects affected by diabetic macular edema (DME) resistant to anti-vascular endothelial growth factor (VEGF) therapy. METHODS: Thirty-two DME patients were enrolled.
Carnovale, Anna +7 more
core +1 more source
Micro-implant d'acétonide de fluocinolone (ILUVIEN(®)) pour l'oedème maculaire diabétique chronique [Fluocinolone acetonide (ILUVIEN®) micro-implant for chronic diabetic macular edema]. [PDF]
, 2015 Diabetic macular edema (DME) is a frequent complication of diabetic retinopathy and may cause severe visual loss. In this article, we examine the pathophysiology of DME and review various treatment options, such as laser photocoagulation, anti-vascular ...
Behar-Cohen, F., Soubrane, G.
core +1 more source
Intravitreal Fluocinolone Acetonide for Diabetic Macular Edema: Long-Term Effect and Structure/Function Correlation [PDF]
, 2022 The long-term effect of intravitreal Fluocinolone acetonide (FAc) on retinal morphology and function in diabetic macular edema (DME) was investigated. Seventeen eyes of twelve consecutive DME patients, treated by intravitreal FAc, were retrospectively ...
Falsini, Benedetto (ORCID:0000-0002-3569-4968) +4 more
core +1 more source
Frontiers in Pharmacology, 2022 Background: To compare the efficacy and safety of advanced intravitreal therapeutic regimens, including a dexamethasone implant at 350 and 700 μg; a fluocinolone acetonide (FA) implant, 0.2 µg/day, 0.59 and 2.1 mg; intravitreal bevacizumab, 1.25 mg ...
Weiting Liao +4 more
doaj +1 more source
Anti-Inflammatory Effect of Dexamethasone Controlled Released From Anterior Suprachoroidal Polyurethane Implants on Endotoxin-Induced Uveitis in Rats. [PDF]
, 2016 Targeted drug delivery to the ocular tissues remains a challenge. Biodegradable intraocular implants allow prolonged controlled release of drugs directly into the eye. In this study, we evaluated an anterior suprachoroidal polyurethane implant containing
Ayres, E. +13 more
core +2 more sources
Therapeutic approaches with intravitreal injections in geographic atrophy secondary to age-related macular degeneration: current drugs and potential molecules [PDF]
, 2019 The present review focuses on recent clinical trials that analyze the efficacy of intravitreal therapeutic agents for the treatment of dry age-related macular degeneration (AMD), such as neuroprotective drugs, and complement inhibitors, also called ...
Cerini, Alberto +5 more
core +1 more source